3 news items
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
ZLAB
14 May 24
License Application (sBLA) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of chronic inflammatory
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
CRDF
JNJ
NTBL
9 May 24
with diabetes, including 28.5 million adults. As the population ages, there will be a higher prevalence of chronic diseases such as diabetes and obesity
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
ZLAB
27 Feb 24
:
Efgartigimod SC in chronic inflammatory demyelinating polyneuropathy (CIDP
- Prev
- 1
- Next